ES2332470T3 - Derivados de tiofeno sustituidos como antagonistas del receptor de glucagon, preparacion y usos terapeuticos. - Google Patents

Derivados de tiofeno sustituidos como antagonistas del receptor de glucagon, preparacion y usos terapeuticos. Download PDF

Info

Publication number
ES2332470T3
ES2332470T3 ES06720513T ES06720513T ES2332470T3 ES 2332470 T3 ES2332470 T3 ES 2332470T3 ES 06720513 T ES06720513 T ES 06720513T ES 06720513 T ES06720513 T ES 06720513T ES 2332470 T3 ES2332470 T3 ES 2332470T3
Authority
ES
Spain
Prior art keywords
thiophene
acid
biphenyl
carbonyl
dimethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES06720513T
Other languages
English (en)
Spanish (es)
Inventor
Mark Donald Chappell
Scott Eugene Conner
Allie Edward Tripp
Guoxin Zhu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36694345&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2332470(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Application granted granted Critical
Publication of ES2332470T3 publication Critical patent/ES2332470T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ES06720513T 2005-02-11 2006-02-09 Derivados de tiofeno sustituidos como antagonistas del receptor de glucagon, preparacion y usos terapeuticos. Expired - Lifetime ES2332470T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65249205P 2005-02-11 2005-02-11
US652492P 2005-02-11

Publications (1)

Publication Number Publication Date
ES2332470T3 true ES2332470T3 (es) 2010-02-05

Family

ID=36694345

Family Applications (1)

Application Number Title Priority Date Filing Date
ES06720513T Expired - Lifetime ES2332470T3 (es) 2005-02-11 2006-02-09 Derivados de tiofeno sustituidos como antagonistas del receptor de glucagon, preparacion y usos terapeuticos.

Country Status (25)

Country Link
US (1) US8084489B2 (enExample)
EP (1) EP1856090B1 (enExample)
JP (1) JP4988604B2 (enExample)
KR (1) KR20070104409A (enExample)
CN (1) CN101115735B (enExample)
AT (1) ATE445609T1 (enExample)
AU (1) AU2006213894B2 (enExample)
BR (1) BRPI0607015A2 (enExample)
CA (1) CA2597073C (enExample)
CR (1) CR9304A (enExample)
CY (1) CY1109624T1 (enExample)
DE (1) DE602006009773D1 (enExample)
DK (1) DK1856090T3 (enExample)
EA (1) EA200701705A1 (enExample)
ES (1) ES2332470T3 (enExample)
IL (1) IL184932A0 (enExample)
MA (1) MA29432B1 (enExample)
MX (1) MX2007009661A (enExample)
NO (1) NO20074567L (enExample)
PL (1) PL1856090T3 (enExample)
PT (1) PT1856090E (enExample)
SI (1) SI1856090T1 (enExample)
TN (1) TNSN07313A1 (enExample)
WO (1) WO2006086488A2 (enExample)
ZA (1) ZA200706354B (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1758853T3 (da) * 2004-06-14 2010-04-06 Lilly Co Eli Glucagon-receptorantagonister, fremstilling og terapeutiske anvendelser
WO2008098244A1 (en) 2007-02-09 2008-08-14 Metabasis Therapeutics, Inc. Novel antagonists of the glucagon receptor
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
CN104803891B (zh) 2008-08-13 2017-10-20 症变治疗公司 胰高血糖素拮抗剂
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
MX2013006768A (es) 2010-12-23 2013-07-22 Pfizer Moduladores de receptor de glucagon.
ES2597972T3 (es) 2011-02-08 2017-01-24 Pfizer Inc Modulador del receptor de glucagón
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
RU2013157388A (ru) 2011-07-22 2015-08-27 Пфайзер Инк. Хинолинильные модуляторы глюкагонового рецептора
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
TW201427658A (zh) 2012-12-10 2014-07-16 Merck Sharp & Dohme 藉由投予升糖素受體拮抗劑及膽固醇吸收抑制劑治療糖尿病之方法
EP3065736B1 (en) 2013-11-04 2018-11-14 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions thereof, and methods of use
JP2017519000A (ja) 2014-06-12 2017-07-13 リガンド・ファーマシューティカルズ・インコーポレイテッド グルカゴンアンタゴニスト
US10829519B2 (en) 2015-09-18 2020-11-10 Wake Forest University Health Sciences Angiotensin (1-7) analogs and methods relating thereto
WO2017059863A1 (en) 2015-10-05 2017-04-13 Hettwer Holding Aps Compositions and methods for treatment of bone defects
CA2914601A1 (en) * 2015-12-11 2017-06-11 Wake Forest University Health Sciences Angiotensin-(1-7) analogs and methods relating thereto
JP7173962B2 (ja) 2016-08-30 2022-11-16 リジェネロン・ファーマシューティカルズ・インコーポレイテッド グルカゴン受容体シグナル伝達の干渉による重度のインスリン抵抗性の処置方法
US20190248888A1 (en) 2016-10-20 2019-08-15 Regeneron Pharmaceuticals, Inc. Methods of lowering blood glucose levels
CA3071387A1 (en) 2017-08-22 2019-02-28 Regeneron Pharmaceuticals, Inc. Methods of treating urea cycle disorders by interfering with glucagon receptor signaling
JP2021513564A (ja) 2018-02-13 2021-05-27 リガンド・ファーマシューティカルズ・インコーポレイテッド グルカゴン受容体拮抗薬
CN118496197A (zh) 2019-12-20 2024-08-16 拜耳公司 取代的噻吩甲酰胺、噻吩甲酸及其衍生物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1463715A1 (en) * 2001-12-03 2004-10-06 Novo Nordisk A/S Novel glucagon antagonists
JP2006500325A (ja) 2002-06-27 2006-01-05 ノボ　ノルディスク　アクティーゼルスカブ 新規なグルカゴンアンタゴニスト
US7989457B2 (en) * 2004-05-28 2011-08-02 Eli Lilly And Company Glucagon receptor antagonists, preparation and therapeutic uses
DK1758853T3 (da) * 2004-06-14 2010-04-06 Lilly Co Eli Glucagon-receptorantagonister, fremstilling og terapeutiske anvendelser

Also Published As

Publication number Publication date
NO20074567L (no) 2007-11-08
JP4988604B2 (ja) 2012-08-01
EP1856090A2 (en) 2007-11-21
AU2006213894B2 (en) 2011-12-08
DK1856090T3 (da) 2009-11-30
CN101115735B (zh) 2013-01-09
EA200701705A1 (ru) 2008-02-28
CY1109624T1 (el) 2014-08-13
JP2008530102A (ja) 2008-08-07
ATE445609T1 (de) 2009-10-15
MA29432B1 (fr) 2008-05-02
IL184932A0 (en) 2007-12-03
WO2006086488A3 (en) 2006-12-14
CA2597073C (en) 2014-11-25
DE602006009773D1 (de) 2009-11-26
MX2007009661A (es) 2007-09-25
SI1856090T1 (sl) 2010-02-26
ZA200706354B (en) 2008-11-26
AU2006213894A1 (en) 2006-08-17
PL1856090T3 (pl) 2010-02-26
EP1856090B1 (en) 2009-10-14
PT1856090E (pt) 2009-11-18
KR20070104409A (ko) 2007-10-25
CR9304A (es) 2008-03-31
CA2597073A1 (en) 2006-08-17
US8084489B2 (en) 2011-12-27
WO2006086488A2 (en) 2006-08-17
US20100137417A1 (en) 2010-06-03
TNSN07313A1 (en) 2008-12-31
CN101115735A (zh) 2008-01-30
BRPI0607015A2 (pt) 2009-12-01

Similar Documents

Publication Publication Date Title
JP4988604B2 (ja) グルカゴン受容体アンタゴニストとしての置換チオフェン誘導体、その調製及び治療への使用
ES2339599T3 (es) Antagonistas del receptor de glucagon, preparacion y usos terapeuticos.
ES2391109T3 (es) Antagonistas del receptor de glucagón, preparación y usos terapéuticos
ES2393757T3 (es) Antagonistas de receptor de glucagón, preparación y usos terapéuticos
ES2516691T3 (es) Antagonistas del receptor de glucagón, preparación y usos terapéuticos
CN1968921B (zh) 胰高血糖素受体拮抗剂、制备和治疗用途
ES2428538T3 (es) Antagonistas del receptor de glucagón, preparación y usos terapéuticos
ES2346246T3 (es) Antagonistas del receptor de glucagon, preparacion y usos terapeuticos.
EP1951659B1 (en) Glucagon receptor antagonists, preparation and therapeutic uses
MX2008006699A (en) Glucagon receptor antagonists, preparation and therapeutic uses